ticlopidine has been researched along with Heart Defects, Congenital in 7 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Testing platelet function makes clopidogrel dosing safer, and simplifies therapy adjustments in long-term treatment." | 2.77 | Prophylactic use of clopidogrel in paediatric cardiac patients. ( Grohmann, J; Hanke, CA; Nakamura, L; Stiller, B; Zieger, B, 2012) |
| "To review a pediatric experience with the antiplatelet agent clopidogrel and suggest a dosage regimen." | 1.33 | Clopidogrel use in children. ( Avner, M; Benson, LN; Finkelstein, Y; Koren, G; Nurmohamed, L, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wessel, DL | 1 |
| Berger, F | 1 |
| Li, JS | 1 |
| Dähnert, I | 1 |
| Rakhit, A | 1 |
| Fontecave, S | 1 |
| Newburger, JW | 1 |
| Wilson, SR | 1 |
| Kronzon, I | 1 |
| Machnicki, SC | 1 |
| Ruiz, CE | 1 |
| Maltz, LA | 1 |
| Gauvreau, K | 1 |
| Connor, JA | 1 |
| Jenkins, KJ | 1 |
| Abdulla, RI | 1 |
| Gentilomo, C | 1 |
| Huang, YS | 1 |
| Raffini, L | 1 |
| Hanke, CA | 1 |
| Stiller, B | 1 |
| Nakamura, L | 1 |
| Grohmann, J | 1 |
| Zieger, B | 1 |
| Finkelstein, Y | 1 |
| Nurmohamed, L | 1 |
| Avner, M | 1 |
| Benson, LN | 1 |
| Koren, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| International Randomized Double Blind Study Evaluating the Efficacy and the Safety of Clopidogrel 0.2 mg/kg Once Daily Versus Placebo in Neonates and Infants With Cyanotic Congenital Heart Disease Palliated With Systemic to Pulmonary Artery Shunt[NCT00396877] | Phase 3 | 906 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
For all reported bleeding events, the type and the etiology of the bleeding event were collected. Participants who experienced bleeding events during the 'on-treatment period' were counted by bleeding type and etiology. Participants who had multiple bleedings could be counted several times. (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Spontaneous | Post-traumatic | Puncture (vascular access site) | Surgical | |
| Clopidogrel 0.2 mg/kg/Day | 56 | 11 | 9 | 17 |
| Placebo | 60 | 6 | 19 | 10 |
"The primary endpoint was the first occurence of any of the following events: Death (including heart transplant); Shunt thrombosis requiring intervention; Hospitalization for bi-directional Glenn procedure or any cardiac related intervention prior to 120 days of age following an event or a shunt narrowing considered to be of thrombotic nature by the blinded adjudication committee.~Only the first event was counted." (NCT00396877)
Timeframe: Median follow-up of 5.8 months (up to a maximum of 12 months after randomization)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Death / Shunt Thrombosis / Cardiac Procedure | - Death | - Shunt thrombosis | - Cardiac procedure <120 days of thrombotic nature | |
| Clopidogrel 0.2 mg/kg/Day | 89 | 51 | 26 | 12 |
| Placebo | 90 | 60 | 21 | 9 |
"Bleeding events spanning from signature of the Informed Consent Form up to the last visit were collected as for any Adverse Event.~The 'on-treatment' period was defined as the period from randomization up until 28 days after treatment discontinuation or final follow-up visit, whichever came first, and participants who experienced bleeding events during that period were counted." (NCT00396877)
Timeframe: From randomization up to 28 days after treatment discontinuation or final follow-up visit, whichever comes first
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Any bleeding event | - Serious | - Serious with an outcome of death | - Leading to permanent treatment discontinuation | |
| Clopidogrel 0.2 mg/kg/Day | 87 | 30 | 1 | 9 |
| Placebo | 88 | 32 | 1 | 9 |
2 trials available for ticlopidine and Heart Defects, Congenital
| Article | Year |
|---|---|
Clopidogrel in infants with systemic-to-pulmonary-artery shunts.
Topics: Anastomosis, Surgical; Clopidogrel; Double-Blind Method; Female; Follow-Up Studies; Heart Defects, C | 2013 |
Prophylactic use of clopidogrel in paediatric cardiac patients.
Topics: Aspirin; Child; Child, Preschool; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combi | 2012 |
5 other studies available for ticlopidine and Heart Defects, Congenital
| Article | Year |
|---|---|
A constrained heart: a case of sudden onset unrelenting chest pain.
Topics: Analgesics, Opioid; Aspirin; Chest Pain; Clopidogrel; Coronary Angiography; Drug Therapy, Combinatio | 2014 |
Clopidogrel in a pediatric population: prescribing practice and outcomes from a single center.
Topics: Adolescent; Child; Child Welfare; Child, Preschool; Clopidogrel; Coronary Thrombosis; Drug Prescript | 2009 |
Propagating knowledge: the value of the single center experience.
Topics: Cardiology; Child; Child Welfare; Clopidogrel; Heart Defects, Congenital; Humans; Pediatrics; Ticlop | 2009 |
Significant increase in clopidogrel use across U.S. children's hospitals.
Topics: Adolescent; Child; Child, Preschool; Clopidogrel; Coronary Thrombosis; Databases, Factual; Drug Ther | 2011 |
Clopidogrel use in children.
Topics: Adolescent; Cardiac Catheterization; Child; Child, Preschool; Clopidogrel; Drug Administration Sched | 2005 |